Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford University has opened a £200 million world-class teaching and research facility with the potential to tackle global challenges of life and mind.

View of the Life and Mind building and the Oxford skyline © NBBJ/ Ty Cole

The Life and Mind building, enabled by Legal & General (L&G), is one of the largest building projects in the University’s history and will be home to the Departments of Biology and Experimental Psychology, as well as the Ineos Oxford Institute for antimicrobial research (IOI). Designed by internationally-renowned architecture practice NBBJ, it will enable researchers to investigate the most fundamental questions of our age – from what it means to be human, to how we address the global challenges of climate change, biodiversity loss, mental health and food security.  

The Life and Mind building was developed and funded by L&G and has been delivered through the Oxford University Development (OUD) partnership – a £4 billion joint venture between Oxford University and Legal & General delivering academic and research facilities, alongside housing and associated infrastructure. 

Opening to coincide with the new academic year, the building offers over 269,000 sq ft of transformative spaces for teaching, research, innovation and public engagement. It will provide a home for more than 1,400 scientists, academics, researchers, support staff and postgraduate students and become the main teaching location for around 1,000 undergraduate students with new lecture halls and teaching spaces. 

Researchers will study both ‘life’ – through the natural world – and ‘mind’ – by exploring the workings of the human brain and behaviour. Among the new research facilities are sleep labs, a virtual reality and motor lab, experimental classrooms, multisensory labs, rooftop glasshouses, licensed facilities for advanced plant science and controlled-environment laboratories, as well as a dedicated home for the University’s botanical collections comprising approximately one million specimens. 

 

 

Read the full story on the University of Oxford website. 

Similar stories

First clinical study in GSK-Oxford Experimental Medicine Collaboration starts as first patient dosed in ulcerative colitis experimental trial

The first patient in the PEGASUS clinical study, part of the GSK-University of Oxford Experimental Medicine Collaboration, received the first dose last week, on 8 October 2026.

Wearable chest patch could support hospital-level care at home, study finds

Researchers in Oxford have shown that wearable chest patches can be used to effectively monitor vital signs in many acutely unwell patients receiving hospital-level care in their own homes.

Brain immune cells protect neurons in Parkinson’s disease by “nibbling” harmful material

New research, published in Science Translational Medicine, reveals how a specialised population of the brain’s immune cells can remove harmful protein clumps from nerve cells (neurons), pointing to potential new treatments for Parkinson’s disease.

Phase I clinical study of ChAdOx1 BDBV vaccine launches in Uganda

The Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine (MRC/UVRI & LSHTM Uganda Research Unit) has launched a Phase I clinical study evaluating the safety and immunogenicity of a candidate vaccine against Bundibugyo virus disease (BVD), a severe form of Ebola virus disease caused by Bundibugyo virus (BDBV), in partnership with the University of Oxford.

The Nuffield Department of Women's & Reproductive Health's Clinical Research Group recruits its 2,000th participant to the Generation Study

Oxford’s Clinical Research Group (CRG) has reached an important milestone after recruiting its 2,000th participant to the nationwide Generation Study.

Dementias Platform UK (DPUK) blood biomarker project takes next step towards NHS dementia diagnosis

A project involving researchers from the Universities of Oxford and Cambridge, Imperial College London and Dementias Platform UK (DPUK) has been selected for a major UK initiative aimed at improving dementia diagnosis and helping more people access the support and treatment they need sooner.